BeiGene presents new research from Tislelizumab program at 2023 ASCO

BeiGene "will share clinical data and patient-reported outcomes for its PD-1 inhibitor, tislelizumab, at the 2023 ASCO Gastrointestinal Cancers Symposium, notably, an oral presentation for interim results of the global pivotal phase 3 trial RATIONALE 305 of tislelizumab in combination with chemotherapy in first-line gastric or gastroesophageal junction cancer. At the interim analysis, RATIONALE 305 trial met one of the primary endpoints of overall survival in patients with G/GEJ whose tumors express PD-L1."